Aug 2026· Scientific Reports· Vol 16· 0 citations· 42 references
Medicine
TL;DR
GNG12 was found to be broadly downregulated in TNBC and associated with suppression of malignant cellular phenotypes; however, its clinical significance and mechanistic relationship with PI3K/AKT signaling require further validation in larger cohorts and additional experimental models.
Abstract
Guanine nucleotide-binding protein subunit gamma-12 (GNG12), a G protein γ-subunit, has been identified as a potential regulator of tumor biology. However, its functional relevance in triple-negative breast cancer (TNBC) remains unclear. In this study, we integrated pan-cancer transcriptomic analyses with experimental validation in TNBC models to investigate the expression patterns, clinicopathological significance, and biological roles of GNG12. GNG12 was found to be broadly downregulated across diverse cancer types, and its reduced expression was significantly associated with unfavorable patient survival outcomes. Low GNG12 expression correlated with adverse clinicopathological features in breast cancer (BRCA). Moreover, it was associated with poorer outcomes in TNBC patient cohorts. Functional assays demonstrated that GNG12 overexpression inhibited TNBC cell proliferation, migration, and invasion, whereas GNG12 knockdown exerted the opposite effects. Pathway analysis and western blotting indicated that GNG12 expression was associated with altered PI3K/AKT pathway activity. Additionally, mutations at S2 and S33—both located within predicted phosphorylation sites—were identified as candidate regulatory alterations whose functional relevance requires further validation. Moreover, GNG12 expression was positively correlated with RNA methylation-related markers and inversely associated with promoter methylation. Taken together, GNG12 was downregulated in TNBC and associated with suppression of malignant cellular phenotypes; however, its clinical significance and mechanistic relationship with PI3K/AKT signaling require further validation in larger cohorts and additional experimental models.
CCNE1 overexpression characterises a clinically aggressive subset of breast cancers, particularly TNBC, and targeting mTORC1 may represent a promising therapeutic approach in CCNE1-high, TP53-mutated, and RB1-deficient tumours, supporting the clinical utility of CCNE1 in patient stratification and targeted therapy.
Nigar Pelin Makas, N. Belder, Özge Akbulut-Çalışkan et al.· Clinical and Translational O...· 0 citations
Elevated TPD52 expression was associated with longer overall survival in specific subgroups, including the basal-like subtype, invasive lobular carcinoma, and N0/N1 stages, and a random forest-based diagnostic model demonstrated high accuracy across multiple datasets.
J. Yu, Z. Zhu, R. Deng et al.· medRxiv· 0 citations
Mechanistic and in vivo evidence linking EI24 to AKT pathway regulation is provided and supports further investigation of EI24-based approaches as potential therapeutic strategies for AKT-driven TNBC.
T. Nam, You Min Kim, Hye Mi Park et al.· Frontiers in Oncology· 0 citations
Findings identify IFITM3 as a regulator of β-catenin localization and Wnt signaling that promotes epithelial-mesenchymal transition (EMT) and stem-like properties in TNBC cells.
Heeyeon Kim, Young-Ming Yu, Y-U Park et al.· Biochemical and Biophysical...· 0 citations
A novel EFO2/USF1/SLC2A1 signaling axis that modulates glycolytic metabolism and CD8⁺T cell cytotoxicity is identified, positioning EFO2 as a promising therapeutic target for TNBC treatment.
Lin Jia, Liru Li, Junning Peng et al.· Biochemical Pharmacology· 0 citations
Analysis of GAPDHP65 in TNBC cells suggested that GAPDHP65 supports tumor growth by influencing apoptosis and cell cycle progression, and downstream molecular changes following GAPDHP65 loss are investigated.
Roberto Aguilar, Christina Baek, Cailyn Hua· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.